InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.66
(
-0.29%
)
Bitcoin
58,799.77
(
-2.26%
)
Post# of 252478
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

kamehameha

Send PM Follow Ignore
Followers 4
Posts 134
Boards Moderated 0
Alias Born 05/16/2011

kamehameha

Re: genisi post# 131275

Thursday, 11/17/2011 5:21:39 AM

Thursday, November 17, 2011 5:21:39 AM

Post# of 252478

500 treatment-naïve GT 2/3 patients



just wonder why only for GT 2/3? another possible restriction on the label - no GT 1 patients.

may be VRUS just wants to avoid a control group with Vertex or Merck products. may work in clinical trials, but physicians most likely will ask for such a comparison.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up